Daicel Corporation (TYO:4202)

Market Cap	314.01B +9.7%
Revenue (ttm)	578.81B +0.4%
Net Income	41.14B -26.1%
EPS	155.25 -23.2%
Shares Out	255.40M
PE Ratio	7.92
Forward PE	7.88
Dividend	60.00 (4.88%)
Ex-Dividend Date	Mar 30, 2026

Volume	1,479,200
Average Volume	1,094,365
Open	1,224.00
Previous Close	1,232.00
Day's Range	1,210.50 - 1,230.00
52-Week Range	1,137.50 - 1,658.00
Beta	0.53
RSI	40.46
Earnings Date	May 12, 2026

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1919
• Employees: 11,178
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4202

Financial Performance

In fiscal year 2025, Daicel's revenue was 586.53 billion, an increase of 5.10% compared to the previous year's 558.06 billion. Earnings were 49.48 billion, a decrease of -11.38%.